|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.13 USD | +1.13% |
|
-3.30% | -17.68% |
| 06-29 | CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says | MT |
| 06-29 | BofA Downgrades CONMED to Underperform From Neutral, Keeps $40 Price Target | MT |
Company Valuation: CONMED Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 4,146 | 2,702 | 3,368 | 2,114 | 1,257 | 986.4 | - | - |
| Change | - | -34.83% | 24.64% | -37.22% | -40.53% | -21.55% | - | - |
| Enterprise Value (EV) 1 | 4,810 | 3,728 | 4,317 | 2,995 | 2,051 | 1,680 | 1,565 | 1,439 |
| Change | - | -22.5% | 15.81% | -30.62% | -31.52% | -18.09% | -6.84% | -8.1% |
| P/E | 73.1x | -33.1x | 53.7x | 16.1x | 26.9x | 8.23x | 7.07x | 6.35x |
| PBR | 5.26x | 3.57x | 4.04x | 2.2x | 1.1x | 0.83x | 0.73x | 0.64x |
| PEG | - | 0x | -0x | 0x | -0.4x | 0x | 0.4x | 0.6x |
| Capitalization / Revenue | 4.1x | 2.58x | 2.71x | 1.62x | 0.91x | 0.72x | 0.69x | 0.65x |
| EV / Revenue | 4.76x | 3.57x | 3.47x | 2.29x | 1.49x | 1.23x | 1.09x | 0.95x |
| EV / EBITDA | 24.4x | 19.8x | 18.3x | 11.3x | 7.44x | 6.15x | 5.32x | 5.19x |
| EV / EBIT | 33.6x | 28.4x | 24.8x | 14.8x | 9.5x | 8.28x | 7.05x | 5.84x |
| EV / FCF | 49.6x | 322x | 40.6x | 19.5x | 13.6x | 8.63x | 9.55x | 8.27x |
| FCF Yield | 2.01% | 0.31% | 2.46% | 5.14% | 7.36% | 11.6% | 10.5% | 12.1% |
| Dividend per Share 2 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | - | - | - |
| Rate of return | 0.56% | 0.9% | 0.73% | 1.17% | 1.97% | - | - | - |
| EPS 2 | 1.94 | -2.68 | 2.04 | 4.25 | 1.51 | 3.98 | 4.635 | 5.16 |
| Distribution rate | 41.2% | -29.9% | 39.2% | 18.8% | 53% | - | - | - |
| Net sales 1 | 1,011 | 1,045 | 1,245 | 1,307 | 1,375 | 1,362 | 1,433 | 1,514 |
| EBITDA 1 | 197.2 | 188.7 | 235.4 | 265.6 | 275.9 | 273.2 | 294.4 | 277.2 |
| EBIT 1 | 143.3 | 131.3 | 174.4 | 202.8 | 216 | 203 | 221.9 | 246.4 |
| Net income 1 | 62.54 | -80.58 | 64.46 | 132.4 | 47.06 | 120.5 | 140.1 | 153.6 |
| Net Debt 1 | 663.8 | 1,026 | 949.6 | 881.3 | 794.1 | 694 | 579 | 452.2 |
| Reference price 2 | 141.76 | 88.64 | 109.51 | 68.44 | 40.60 | 32.76 | 32.76 | 32.76 |
| Nbr of stocks (in thousands) | 29,247 | 30,482 | 30,752 | 30,891 | 30,968 | 30,109 | - | - |
| Announcement Date | 1/26/22 | 2/2/23 | 1/31/24 | 2/5/25 | 1/28/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 8.23x | 1.23x | 6.15x | -.--% | 986M | |
| 22.8x | 3.43x | 12.87x | 2.76% | 161B | |
| 17.95x | 3.16x | 11.13x | 3.74% | 101B | |
| 15.86x | 0.18x | 11.37x | 0.82% | 56.12B | |
| 32.74x | 7.95x | 20.8x | 1.23% | 53.35B | |
| 38.1x | 3.02x | 10.38x | 2.52% | 42.13B | |
| 39.95x | 1.44x | 12.67x | 0.2% | 35.29B | |
| 28.13x | 5.01x | 15.96x | -.--% | 26.57B | |
| 43.35x | 7.52x | 27.13x | 0.25% | 25.79B | |
| 23.36x | 3.42x | 12.28x | 1.24% | 20.69B | |
| Average | 27.05x | 3.64x | 14.07x | 1.28% | 52.29B | |
| Weighted average by Cap. | 25.80x | 3.60x | 13.79x | 2.06% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CNMD Stock
- Valuation CONMED Corporation
Select your edition
All financial news and data tailored to specific country editions
